Immunohistochemical detection of proliferating cell nuclear antigen (PCNA)/cyclin in human prostate adenocarcinoma. 1993

R Nemoto, and H Kawamura, and I Miyakawa, and K Uchida, and K Hattori, and K Koiso, and M Harada
Department of Urology, Tottori University School of Medicine, Yonago, Japan.

Tissue specimens from 12 patients with adenocarcinoma of the prostate and 7 patients with benign prostate hypertrophy were stained by an indirect immunoperoxidase method using antiproliferating cell nuclear antigen (PCNA) monoclonal antibody. The PCNA labeling index was determined by counting the number of PCNA-labeled cells in the tissue sections. Average PCNA labeling index of the benign prostate hypertrophy was 1.2 +/- 0.5%. Poorly differentiated tumors averaged 7.6 +/- 3.9% labeling versus 4.6 +/- 1.3% in moderately differentiated tumors, and well differentiated tumor in the series had a PCNA labeling index of 2.5 +/- 0.9%. The PCNA labeling indices for atypical hyperplasia were 1.9, and 4.1%, respectively. Our preliminary results suggest that the measurement of PCNA labeling index in prostate cancer may prove to be a new objective and quantitative assay of biological potential of individual tumor.

UI MeSH Term Description Entries
D007150 Immunohistochemistry Histochemical localization of immunoreactive substances using labeled antibodies as reagents. Immunocytochemistry,Immunogold Techniques,Immunogold-Silver Techniques,Immunohistocytochemistry,Immunolabeling Techniques,Immunogold Technics,Immunogold-Silver Technics,Immunolabeling Technics,Immunogold Silver Technics,Immunogold Silver Techniques,Immunogold Technic,Immunogold Technique,Immunogold-Silver Technic,Immunogold-Silver Technique,Immunolabeling Technic,Immunolabeling Technique,Technic, Immunogold,Technic, Immunogold-Silver,Technic, Immunolabeling,Technics, Immunogold,Technics, Immunogold-Silver,Technics, Immunolabeling,Technique, Immunogold,Technique, Immunogold-Silver,Technique, Immunolabeling,Techniques, Immunogold,Techniques, Immunogold-Silver,Techniques, Immunolabeling
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009687 Nuclear Proteins Proteins found in the nucleus of a cell. Do not confuse with NUCLEOPROTEINS which are proteins conjugated with nucleic acids, that are not necessarily present in the nucleus. Nucleolar Protein,Nucleolar Proteins,Nuclear Protein,Protein, Nuclear,Protein, Nucleolar,Proteins, Nuclear,Proteins, Nucleolar
D011471 Prostatic Neoplasms Tumors or cancer of the PROSTATE. Cancer of Prostate,Prostate Cancer,Cancer of the Prostate,Neoplasms, Prostate,Neoplasms, Prostatic,Prostate Neoplasms,Prostatic Cancer,Cancer, Prostate,Cancer, Prostatic,Cancers, Prostate,Cancers, Prostatic,Neoplasm, Prostate,Neoplasm, Prostatic,Prostate Cancers,Prostate Neoplasm,Prostatic Cancers,Prostatic Neoplasm
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000230 Adenocarcinoma A malignant epithelial tumor with a glandular organization. Adenocarcinoma, Basal Cell,Adenocarcinoma, Granular Cell,Adenocarcinoma, Oxyphilic,Adenocarcinoma, Tubular,Adenoma, Malignant,Carcinoma, Cribriform,Carcinoma, Granular Cell,Carcinoma, Tubular,Adenocarcinomas,Adenocarcinomas, Basal Cell,Adenocarcinomas, Granular Cell,Adenocarcinomas, Oxyphilic,Adenocarcinomas, Tubular,Adenomas, Malignant,Basal Cell Adenocarcinoma,Basal Cell Adenocarcinomas,Carcinomas, Cribriform,Carcinomas, Granular Cell,Carcinomas, Tubular,Cribriform Carcinoma,Cribriform Carcinomas,Granular Cell Adenocarcinoma,Granular Cell Adenocarcinomas,Granular Cell Carcinoma,Granular Cell Carcinomas,Malignant Adenoma,Malignant Adenomas,Oxyphilic Adenocarcinoma,Oxyphilic Adenocarcinomas,Tubular Adenocarcinoma,Tubular Adenocarcinomas,Tubular Carcinoma,Tubular Carcinomas
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000369 Aged, 80 and over Persons 80 years of age and older. Oldest Old
D000911 Antibodies, Monoclonal Antibodies produced by a single clone of cells. Monoclonal Antibodies,Monoclonal Antibody,Antibody, Monoclonal

Related Publications

R Nemoto, and H Kawamura, and I Miyakawa, and K Uchida, and K Hattori, and K Koiso, and M Harada
October 1993, Zhonghua wai ke za zhi [Chinese journal of surgery],
R Nemoto, and H Kawamura, and I Miyakawa, and K Uchida, and K Hattori, and K Koiso, and M Harada
June 1987, Journal of immunology (Baltimore, Md. : 1950),
R Nemoto, and H Kawamura, and I Miyakawa, and K Uchida, and K Hattori, and K Koiso, and M Harada
June 1993, Pathology, research and practice,
R Nemoto, and H Kawamura, and I Miyakawa, and K Uchida, and K Hattori, and K Koiso, and M Harada
August 1992, Nippon Ganka Gakkai zasshi,
R Nemoto, and H Kawamura, and I Miyakawa, and K Uchida, and K Hattori, and K Koiso, and M Harada
September 1996, European journal of cancer. Part B, Oral oncology,
R Nemoto, and H Kawamura, and I Miyakawa, and K Uchida, and K Hattori, and K Koiso, and M Harada
January 1992, Archives of dermatological research,
R Nemoto, and H Kawamura, and I Miyakawa, and K Uchida, and K Hattori, and K Koiso, and M Harada
January 1987, Neurologia medico-chirurgica,
R Nemoto, and H Kawamura, and I Miyakawa, and K Uchida, and K Hattori, and K Koiso, and M Harada
June 1992, Cell biochemistry and function,
R Nemoto, and H Kawamura, and I Miyakawa, and K Uchida, and K Hattori, and K Koiso, and M Harada
September 1996, Annales de pathologie,
R Nemoto, and H Kawamura, and I Miyakawa, and K Uchida, and K Hattori, and K Koiso, and M Harada
January 1993, Rinsho byori. The Japanese journal of clinical pathology,
Copied contents to your clipboard!